Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 562K 523K 480K 901K 61.26M 913K 6.21M 2.43M 30.25M 2.4M 2.35M 105M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 17.11M 15.93M 14.63M 27.47M 1.87B 27.83M 189M 73.95M 922M 73.08M 71.5M 3.19B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI
29/05/20	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
22/04/20	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
21/04/20	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
30/03/20	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
09/01/20	Motion for Asset Sale Approved for Achaogen, Inc.	CI
29/12/19	Motion for Asset Sale Filed by Achaogen, Inc.	CI
24/09/19	Final DIP Financing Approved for Achaogen, Inc.	CI
29/08/19	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
13/08/19	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
30/07/19	Achaogen, Inc. Announces Management Changes	CI
23/07/19	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.82M 9.14M 8.4M 15.77M 1.07B 15.98M 109M 42.45M 529M 41.95M 41.05M 1.83B	8.73M 7.67M 7.14M 6.56M 12.32M 837M 12.48M 84.9M 33.16M 413M 32.76M 32.06M 1.43B
Net income	-126M -110M -103M -94.41M -177M -12.05B -180M -1.22B -477M -5.95B -472M -461M -20.56B	-187M -164M -153M -140M -263M -17.89B -267M -1.81B -709M -8.83B -700M -685M -30.53B
Net Debt	-143M -126M -117M -107M -202M -13.7B -204M -1.39B -543M -6.76B -536M -525M -23.38B	18.83M 16.55M 15.41M 14.15M 26.57M 1.81B 26.92M 183M 71.53M 892M 70.68M 69.16M 3.08B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news : Achaogen

Financials

Company Profile